Company intelligence / Profile preview

AffaMed Technologies

New York City, New York, United States

Ownership: Private
Employees: ~52
Development stage: Other

Overview

AffaMed Technologies, through its parent AffaMed Therapeutics, has achieved positive late-stage (Phase 3) clinical and real-world results for DEXTENZA (dexamethasone ophthalmic insert) for post-surgical ocular inflammation and pain, as well as an NDA acceptance in Singapore. The company also received regulatory clearance in China for clinical trials for risuteganib (Luminate) in intermediate dry AMD. Medical device programs include exclusive Greater China rights for novel intraocular lenses (IOLs) such as EVOLUX, targeting improved outcomes in cataract surgery.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeMedical deviceBiologic
Industry: Biotech

Partnerships

SIFI S.p.A.

Beyond the preview

Go deeper on AffaMed Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AffaMed Technologies.

Explore the full profile